| アブストラクト | BACKGROUND: Myasthenia gravis (MG), a chronic and unpredictable autoimmune disease, is associated with multiple comorbidities and high disease burden. OBJECTIVE: To assess the disease burden, healthcare resource utilisation (HCRU), and treatment patterns of patients with newly diagnosed MG in England. METHODS: Data from Clinical Practice Research Datalink GP practices linked to the Hospital Episode Statistics database were used. Eligible patients had >/=1 diagnostic code for MG, with the first MG diagnostic code recorded between 01 January 2010 and 31 December 2019. Non-MG controls were selected if they had no recorded MG diagnosis and >/=12 months of data. Controls were matched for age, sex and GP practice in a maximum ratio of 5:1. RESULTS: Mean follow-up duration was 2.8 and 3.1 years for the MG and non-MG cohorts, respectively. In the MG cohort, 56% of patients were male, with a mean age of 67 years at baseline. Incidence rates of all comorbidities assessed during follow-up were higher in the MG cohort than in controls. Almost two-thirds of MG patients experienced >/=1 myasthenic exacerbation during follow-up; incidence rates (95% confidence interval) of MG exacerbations and crises were 50.0 (44.7-55.9) and 1.3 (0.8-2.0) per 100 person-years, respectively. Visits to non-neurology specialists and outpatient clinics were the most common instances of HCRU overall, each being more frequent in the MG cohort than for controls. In the first year of follow-up, acetylcholinesterase inhibitors (AChEIs) and corticosteroids were used by 56.0% and 50.2% of MG patients, respectively; the use of AChEIs declined thereafter. CONCLUSIONS: Despite treatment, there is a high disease burden for patients with newly diagnosed MG in England, with high rates of MG exacerbation and HCRU use. Thus, there is a need for targeted treatments with sustained efficacy and improved safety to adequately manage MG symptoms and reduce MG-related disease burden. |
|---|
| ジャーナル名 | Journal of neuromuscular diseases |
|---|
| Pubmed追加日 | 2025/2/20 |
|---|
| 投稿者 | Bonar, Kerina; Boudiaf, Nada; Zaremba, Piotr; Tarancon, Thais; Zhou, Jiachen; Jacob, Saiju |
|---|
| 組織名 | UCB, Slough, UK.;UCB, Warszawa, Poland.;UCB, Madrid, Spain.;UCB, Cambridge, MA, USA.;Department of Neurology and Centre for Rare Diseases, Institute of Immunology and;Immunotherapy, University Hospitals Birmingham and University of Birmingham,;Birmingham, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39973446/ |
|---|
